PriceTargets.com logo

Enanta Pharmaceuticals - ENTA Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $20.00
  • Forecasted Upside: 73.01%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 1 Strong Buy Ratings
$11.56 As of 10/30/2024 03:53 PM ET
▲ +0.06 (0.52%)

This chart shows the closing price for ENTA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Enanta Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ENTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ENTA

Analyst Price Target is $20.00
▲ +73.01% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Enanta Pharmaceuticals in the last 3 months. The average price target is $20.00, with a high forecast of $27.00 and a low forecast of $10.00. The average price target represents a 73.01% upside from the last price of $11.56.

This chart shows the closing price for ENTA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 5 contributing investment analysts is to moderate buy stock in Enanta Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/8/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/6/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2023
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
5/2/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/31/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/29/2024
  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/29/2024

Latest Recommendations

  • 1 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
10/9/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$22.00 ➝ $22.00
9/27/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$22.00 ➝ $22.00
8/6/2024Evercore ISIUpgradeStrong-Buy
8/6/2024JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$11.00 ➝ $10.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
5/7/2024HC WainwrightLower TargetBuy ➝ Buy$28.00 ➝ $27.00
5/7/2024JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$23.00 ➝ $22.00
2/8/2024JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$12.00 ➝ $11.00
11/22/2023OppenheimerLower TargetMarket Perform ➝ Market Perform$25.00 ➝ $21.00
11/21/2023JMP SecuritiesLower TargetOutperform ➝ Outperform$42.00 ➝ $23.00
11/21/2023HC WainwrightLower TargetBuy ➝ Buy$30.00 ➝ $28.00
10/23/2023HC WainwrightLower TargetBuy ➝ Buy$48.00 ➝ $30.00
10/2/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$25.00 ➝ $15.00
9/19/2023HC WainwrightReiterated RatingBuy ➝ Buy$48.00
8/9/2023OppenheimerLower TargetMarket Perform ➝ Market Perform$30.00 ➝ $25.00
8/9/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$14.00
8/8/2023Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$25.00
8/8/2023HC WainwrightReiterated RatingBuy ➝ Buy$48.00
8/8/2023JMP SecuritiesLower TargetMarket Outperform ➝ Market Outperform$65.00 ➝ $42.00
8/8/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$49.00 ➝ $18.00
5/9/2023Royal Bank of CanadaLower Target$48.00 ➝ $33.00
5/9/2023HC WainwrightLower Target$68.00 ➝ $48.00
5/9/2023JMP SecuritiesLower Target$82.00 ➝ $65.00
3/22/2023Royal Bank of CanadaReiterated RatingSector Perform$54.00
2/9/2023Leerink PartnersReiterated RatingMarket Perform$49.00
2/8/2023Piper SandlerReiterated RatingOverweight$87.00
2/8/2023HC WainwrightBoost Target$56.00 ➝ $68.00
2/8/2023JPMorgan Chase & Co.Lower TargetNeutral$74.00 ➝ $60.00
1/27/2023Leerink PartnersLower TargetMarket Perform$50.00 ➝ $49.00
12/9/2022HC WainwrightInitiated CoverageBuy$56.00
11/24/2022OppenheimerSet Target$50.00
11/22/2022JMP SecuritiesReiterated RatingBuy$96.00
11/22/2022Royal Bank of CanadaLower TargetSector Perform$65.00 ➝ $54.00
8/10/2022OppenheimerBoost TargetMarket Perform$53.00 ➝ $59.00
8/9/2022Royal Bank of CanadaLower TargetSector Perform$67.00 ➝ $66.00
8/9/2022JMP SecuritiesBoost TargetMarket Outperform$103.00 ➝ $137.00
8/1/2022Leerink PartnersBoost TargetMarket Perform$44.00 ➝ $50.00
7/6/2022Evercore ISIUpgradeIn-Line ➝ Outperform$62.00
7/1/2022Royal Bank of CanadaBoost TargetSector Perform$64.00 ➝ $67.00
6/22/2022JMP SecuritiesReiterated RatingBuy$103.00
5/20/2022OppenheimerLower TargetOutperform$70.00 ➝ $45.00
5/19/2022Leerink PartnersLower TargetMarket Perform$58.00 ➝ $44.00
5/19/2022JMP SecuritiesReiterated RatingBuy$114.00 ➝ $103.00
5/19/2022Robert W. BairdLower TargetOutperform$130.00 ➝ $90.00
5/11/2022Roth CapitalLower Target$101.00 ➝ $70.00
3/30/2022JMP SecuritiesReiterated RatingBuy$116.00
2/9/2022Leerink PartnersLower TargetMarket Perform$80.00 ➝ $68.00
1/13/2022Leerink PartnersLower TargetMarket Perform$85.00 ➝ $80.00
1/5/2022JMP SecuritiesReiterated RatingBuy$116.00
11/24/2021OppenheimerBoost TargetMarket Perform$55.00 ➝ $73.00
11/23/2021Roth CapitalLower TargetBuy$107.00 ➝ $101.00
11/23/2021Leerink PartnersLower TargetMarket Perform$92.00 ➝ $85.00
11/23/2021JMP SecuritiesBoost TargetOutperform$111.00 ➝ $116.00
11/19/2021Royal Bank of CanadaLower TargetSector Perform$74.00 ➝ $72.00
11/19/2021JMP SecuritiesLower TargetMarket Outperform$121.00 ➝ $111.00
11/8/2021Leerink PartnersBoost TargetMarket Perform$55.00 ➝ $92.00
11/8/2021JMP SecuritiesBoost TargetMarket Outperform$77.00 ➝ $121.00
11/8/2021Robert W. BairdBoost TargetOutperform$71.00 ➝ $130.00
10/20/2021JMP SecuritiesReiterated RatingBuy$73.00 ➝ $78.00
10/20/2021Royal Bank of CanadaBoost TargetSector Perform$58.00 ➝ $74.00
10/6/2021Jefferies Financial GroupInitiated CoverageBuy$95.00
9/9/2021Leerink PartnersInitiated CoverageMarket Perform$55.00
8/6/2021Royal Bank of CanadaLower TargetSector Perform$52.00 ➝ $50.00
8/6/2021JMP SecuritiesBoost TargetOutperform$70.00 ➝ $77.00
2/9/2021Royal Bank of CanadaBoost TargetIn-Line ➝ Sector Perform$47.00 ➝ $53.00
1/29/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$44.00 ➝ $55.00
11/24/2020Royal Bank of CanadaLower TargetSector Perform$52.00 ➝ $45.00
11/23/2020Evercore ISIInitiated CoverageUnderperform$30.00
10/26/2020Roth CapitalBoost TargetBuy$104.00 ➝ $107.00
9/23/2020OppenheimerReiterated RatingHold$55.00
8/27/2020Roth CapitalReiterated RatingBuy$104.00
8/25/2020Piper SandlerInitiated CoverageOverweight$87.00
8/6/2020Royal Bank of CanadaReiterated RatingHold
8/4/2020OppenheimerInitiated CoverageHold$55.00
7/27/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$70.00
5/7/2020OppenheimerReiterated RatingHold$62.00
4/8/2020Royal Bank of CanadaReiterated RatingHold$49.00
3/17/2020Robert W. BairdUpgradeNeutral ➝ Outperform$60.00
11/22/2019JMP SecuritiesDowngradeOutperform ➝ Market Perform
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.79 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 5 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 3 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/31/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Enanta Pharmaceuticals logo
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Read More

Today's Range

Now: $11.56
Low: $11.46
High: $11.68

50 Day Range

MA: $11.82
Low: $10.05
High: $13.30

52 Week Range

Now: $11.56
Low: $8.08
High: $17.80

Volume

30,000 shs

Average Volume

202,305 shs

Market Capitalization

$244.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Enanta Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Enanta Pharmaceuticals in the last twelve months: Evercore ISI, HC Wainwright, JMP Securities, JPMorgan Chase & Co., Oppenheimer Holdings Inc., and StockNews.com.
View the latest analyst ratings for ENTA.

What is the current price target for Enanta Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Enanta Pharmaceuticals in the last year. Their average twelve-month price target is $20.00, suggesting a possible upside of 73.0%. HC Wainwright has the highest price target set, predicting ENTA will reach $27.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $10.00 for Enanta Pharmaceuticals in the next year.
View the latest price targets for ENTA.

What is the current consensus analyst rating for Enanta Pharmaceuticals?

Enanta Pharmaceuticals currently has 1 sell rating, 1 hold rating, 2 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ENTA.

What other companies compete with Enanta Pharmaceuticals?

Other companies that are similar to Enanta Pharmaceuticals include Genfit, Mesoblast, Arcutis Biotherapeutics, Applied Therapeutics and CARGO Therapeutics. Learn More about companies similar to Enanta Pharmaceuticals.

How do I contact Enanta Pharmaceuticals' investor relations team?

Enanta Pharmaceuticals' physical mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company's listed phone number is (617) 607-0800 and its investor relations email address is [email protected]. The official website for Enanta Pharmaceuticals is www.enanta.com. Learn More about contacing Enanta Pharmaceuticals investor relations.